L-dopa in Parkinson’s disease

  • E. Schneider
Conference paper
Part of the Key Topics in Brain Research book series (KEYTOPICS)


L-dopa at present is the most potent drug in the treatment of Parkinson’s disease (PD). The initiation of L-dopa has brought about an improvement in the quality of life and an increase in life expectancy. After long-term administration a declined efficacy, fluctuations in mobility and dyskinesias are to be seen.

It was supposed that L-dopa by producing toxic radicals may be the cause not only for the long-term treatment failure but also for the progression of the disease. Arguments in favor or against an early use of L-dopa are presented.


Parkinsonian Patient Dopaminergic Lesion Restricted Protein Intake Ingest Amino Acid Brain Dopamine Metabolism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y (1987) Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions? Neurology 37: 1539–1542PubMedGoogle Scholar
  2. Fahn S, Calne DB (1978) Considerations in the management of parkinsonism. Neurology 28: 5–7PubMedGoogle Scholar
  3. Gancher ST, Nutt IG, Woodward WR (1987) Peripheral pharmakokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 37: 940–944PubMedGoogle Scholar
  4. Goetz CG, Tanner CM, Shannon KM (1987) Progression of Parkinson’s disease without levodopa. Neurology 37: 695–698PubMedGoogle Scholar
  5. Guillard A, Chastang C, Fenelon G (1986) Etude à long terme de 416 cas de maladie de parkinson. Facteurs de pronostic et implications thérapeutiques. Rev Neurol (Paris) 142: 207–214Google Scholar
  6. Hoehn MM, Yahr M (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427–442PubMedGoogle Scholar
  7. Hoehn MM (1983) Parkinsonism treated with levodopa, progression and mortality. J Neural Transm [Suppl] 19: 253–264Google Scholar
  8. Juncos JL, Fabbrini G, Mouradian MM, Serrati C, Chase TN (1987) Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol 44: 1003–1005PubMedCrossRefGoogle Scholar
  9. Leenders KL, Palmer AJ, Quinn N, Clark J, Firnau G, Garnett ES, Nahmias C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatr 49: 853–860PubMedCrossRefGoogle Scholar
  10. Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RSJ (1986) Inhibition of L- [18F] Fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 20: 258–262PubMedCrossRefGoogle Scholar
  11. Lesser RP, Fahn S, Snider SR, et al (1979) Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29: 1253–1260PubMedGoogle Scholar
  12. Markham CH, Diamond SG (1981) Evidence to support early levodopa therapy in Parkinson’s disease. Neurology 31: 125–131PubMedGoogle Scholar
  13. Markham CH, Diamond SG (1986) Long-term followup of early DOPA treatment in Parkinson’s disease. Ann Neurol 19: 362–365CrossRefGoogle Scholar
  14. Melamed E (1986) Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 43: 402–405PubMedCrossRefGoogle Scholar
  15. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The on-off phenomenon in Parkinson’s disease. N Engl J Med 310:483–488PubMedCrossRefGoogle Scholar
  16. Nutt JG (1987) On-off phenomenon: Relation to levodopa pharmakokinetics and pharmacodynamics. Ann Neurol 22: 535–540PubMedCrossRefGoogle Scholar
  17. Pincus JH, Barry KM (1987) Plasma levels of amino acids correlate with motor fluctuations in parkinsonism. Arch Neurol 44: 1006–1009PubMedCrossRefGoogle Scholar
  18. Poewe WH, Lees AJ, Stern GM (1986) Low-dose L-dopa therapy in Parkin- son’s disease: A 6-year follow-up study. Neurology 36: 1528–1530PubMedGoogle Scholar
  19. Sage JI, Trooskin S, Heikkila R (1987) Long-term duodenal infusion of levo-dopa for on-off phenomena in parkinsonism: Continued good clinical response associated with gradually declining levodopa in take. Ann Neurol 22: 173Google Scholar
  20. Stern G (1987) Prognosis in Parkinson’s disease. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 91–98Google Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • E. Schneider
    • 1
  1. 1.Department of NeurologyGeneral Hospital Hamburg-HarburgFederal Republic of Germany

Personalised recommendations